Cargando…
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alterations is effective, irrespective of the cancer hi...
Autores principales: | Meric-Bernstam, Funda, Ford, James M., O'Dwyer, Peter J., Shapiro, Geoffrey I., McShane, Lisa M., Freidlin, Boris, O'Cearbhaill, Roisin E., George, Suzanne, Glade-Bender, Julia, Lyman, Gary H., Tricoli, James V., Patton, David, Hamilton, Stanley R., Gray, Robert J., Hawkins, Douglas S., Ramineni, Bhanumati, Flaherty, Keith T., Grivas, Petros, Yap, Timothy A., Berlin, Jordan, Doroshow, James H., Harris, Lyndsay N., Moscow, Jeffrey A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102840/ https://www.ncbi.nlm.nih.gov/pubmed/36662819 http://dx.doi.org/10.1158/1078-0432.CCR-22-3334 |
Ejemplares similares
-
Primary osteosarcoma of the uterus with cardiac and pulmonary metastases
por: Abraham, Cynthia, et al.
Publicado: (2014) -
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer
por: Koneru, Mythili, et al.
Publicado: (2015) -
Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018) -
Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent
por: Huseynov, Aydin, et al.
Publicado: (2019) -
Combo Prospecting
por: Hughes, Tony
Publicado: (2018)